Review of: "Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model"

sabu thomas[1]

1 Mahatma Gandhi University, Kerala

Potential competing interests: The author(s) declared that no potential competing interests exist.

Title: Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model

Authors: Lisette Cornelissen1, Esmee Hoefsmit2, Disha Rao2, Judith Lijnsvelt2, Lucien van Keulen1, Marieke van Es1, Volker Grimm3, René H. Medema2, and Christian U. Blank2

1 Wageningen Bioveterinary Research, Lelystad, The Netherlands

2 The Netherlands Cancer Institute, Amsterdam, The Netherlands

3 Dermatology and Allergology practice, Deggendorf, Germany

Comments

Accept after a major revision

1. Introduction needs to be updated with current scientific literature.
2. Reinfection issues has to be updated with current waves of omicron
3. Dose regimen along with course time of the treatment needs to be standardized from human to animal correlation factor based on human clinical dose.
4. Please discuss why weight loss are occurred at post covid stage, whether any course of NM lipid career treatment can prevent weight loss triggered by covid-19
5. What are your views on the lipid NM carrier-based drug targeting to eradicate the viral load from lungs, nasal location and nasopharyngeal route?
6. However it is an interesting approach and quite relevant topic for therapy against covid-`19 , but in the perspective of 3rd wave of omicron and 2nd wave delta based infection , please discuss how Lipid nano drug delivery with NM could combat v.o.c. STRAIN infection by reducing the chances of fatality.
7. Please read the following paper and improve the discussions.

https://www.biorxiv.org/content/10.1101/2020.11.09.372375v1

https://www.sciencedirect.com/science/article/abs/pii/S2352507X20301062